Devonian Health shows positive preclinical results for lung fibrosis drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
February 10, 2026 9:01 AM ESTPositive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine with anti-fibrotic effects in lungsCompelling results compared to Pirfenidone, a drug used to treat idiopathic pulmonary fibrosis
QUÉBEC, Feb. 10, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD); (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced a potential expanded therapeutic application... More
